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This weekly COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. 
1. Health Evidence Summary 
UK launches whole genome sequence alliance to map spread of 
coronavirus 
Wellcome Sanger Institute | 23 March 2020 | News article 
https://www.sanger.ac.uk/news/view/uk-launches-whole-genome-sequence-alliance-map-
spread-coronavirus 
The newly formed COVID-19 Genomics UK Consortium (COG-UK), comprised of NHS, Public 
Health Agencies and academic institutions, will deliver large scale rapid sequencing of SARS-
CoV-2 to share with the NHS, and the UK Government for decision-making and to make 
openly available to epidemiologists and virologists worldwide. This will provide a “real-time 
view of COVID-19 virus evolution” and to monitor changes in the virus at a national scale to 
understand how the virus is spreading and whether different strains are emerging, as well as 
how human interventions including drug treatments and eventually vaccines, exert pressure 
on the virus. 
Samples from patients with confirmed cases of COVID-19 will be sent to a network of 
sequencing centres which currently includes Birmingham, Belfast, Cambridge, Cardiff, 
Edinburgh, Exeter, Glasgow, Liverpool, London, Norwich, Nottingham, Oxford and 
Sheffield. The Wellcome Trust Sanger Institute will provide large-scale sequencing capacity 
and additional support. 
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WHO launches global megatrial of the four most promising 
coronavirus treatments 
Kupferschmidt | Science | 22 March 2020 | News article 
https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-
promising-coronavirus-treatments 
On 20 March 2020, WHO announced a large global trail, SOLIDARITY, to find out if current 
available drug treatments for other diseases, as well as unapproved drugs that have 
performed well in animal studies with SARS and MERS, can treat or be given prophylactically 
to protect health care workers and others at high risk from COVID-19. WHO is focusing on 
what it says are the four most promising therapies: an experimental antiviral compound called 
remdesivir; the malaria medications chloroquine and hydroxychloroquine; a combination of 
two HIV drugs, lopinavir and ritonavir; and that same combination plus interferon-beta. This 
trial is not double-blind, so there maybe placebo effects but aims to balance scientific rigour 
against speed.  
 
Viral dynamics in mild and severe cases of COVID-19 
Liu et al. | The Lancet Infectious Diseases | 19 March 2020 | Correspondence 
https://doi.org/10.1016/S1473-3099(20)30232-2 
This correspondence reports on viral load from serial testing of different types of clinical 
specimens collected from 82 infected individuals. 
 
COVID-19 vaccine development 
Oxford Vaccine Group | 18 March 2020 | News article 
https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development 
Researchers from the Oxford Vaccine Group and Oxford’s Jenner Institute started work on a 
COVID-19 vaccine on 10 January 2020. A vaccine candidate has been identified, is entering 
animal trials this week, and a safety trial on humans is expected next month. If all goes well, 
work will move to a larger trial to assess how effective the vaccine is at protecting against the 
infection. The vaccine is the chimpanzee adenovirus vaccine vector (ChAdOx1) containing 
the genetic sequence for the coronavirus surface spike protein. Immune responses from other 
coronavirus studies suggest that these are a good target for a vaccine. The well-studied 
ChAdOx1 vaccine type can generate a strong immune response from one dose, is a non-
replicating virus so it cannot cause an ongoing infection in the vaccinated individual, making 
it safer to give to the elderly, anyone with a pre-existing condition such as diabetes, and to 
children, has been used safely in thousands of subjects, a wide age range and in vaccines 
targeting over 10 different diseases. This team has previously developed a vaccine for MERS, 
which has shown promise in early clinical trials. 
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A trial of lopinavir-ritonavir in adults hospitalised with severe 
COVID-19 
Cao et al. | NEJM | 18 March 2020 | Original article 
https://doi.org/10.1056/NEJMoa2001282 
No benefit was observed with lopinavir-ritonavir treatment beyond standard care in 199 
randomised hospitalised adult patients with severe COVID-19. A larger trial could be 
conducted. 
 
Preparedness is essential for malaria-endemic regions during the 
COVID-19 pandemic 
Wang et al. | The Lancet | 16 March 2020 | Comment 
https://doi.org/10.1016/S0140-6736(20)30561-4 
Early symptoms of COVID-19, including fever, myalgia, and fatigue, may be confused with 
malaria and challenge early clinical diagnosis. Malaria endemic countries need to use the time 
window they have to use preventive measures against not only against the COVID-19 threat 
but also its likely impact on existing malaria control efforts, drawing on relevant lessons from 
the 2014-16 outbreak of Ebola. This will require collective political will and coordination by 
African countries. Should there be an outbreak of COVID-19, governments and health leaders 
in malaria-endemic regions must minimise stresses to medical infrastructure; resource 
allocation should be optimised; management of medical supplies and stockpiling of surgical 
masks and other protective equipment should be done in advance and medical staff 
adequately trained in their use. Mass drug administration and the distribution of ITNs could be 
considered for short-term malaria relief in hyperendemic areas in the case of an emergency – 
additionally supporting COVID-19 efforts by reducing the strain on medical resources and 
minimising confounding factors in diagnosis. Malaria diagnostics should be systematically 
added to fever management, including for suspected cases of COVID-19, and health-care 
facilities should be well stoked with artemisinin combination therapy drugs. Infection control, 
such as social distancing, mask-wearing and early seeking of diagnostic testing and necessary 
treatment should be communicated in advance. 
 
Conserving Supply of Personal Protective Equipment – A Call for 
Ideas 
JAMA | 20 March 2020 | Editorial 
https://doi.org/10.1001/jama.2020.4770 
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JAMA is inviting suggestions, which can be added as online comments to this article, for 
creative immediate solutions for how to maximise the use of PPE, to conserve the supply of 
PPE and to identify new sources of PPE. Ideas so far include smaller pack sizes; restrictions 
to institutional purchasers (not individuals) only; adapting snorkel masks, UV germicidal 
irradiation (without damage to masks) so masks can be safely reused; new sources of PPE. 
 
Rational use of face masks in the COVID-19 pandemic 
Feng et al. | The Lancet Respiratory Medicine | 20 March 2020 | Comment 
https://doi.org/10.1016/S2213-2600(20)30134-X 
Authors call for governments and public health agencies to make rational recommendations 
on appropriate face mask use to complement their recommendations on other preventive 
measures, such as hand hygiene. Urgent research on the duration of protection of face masks, 
the measures to prolong life of disposable masks and the invention on reusable masks is 
required. 
 
Scientific evidence published that the Scientific Advisory Group for 
Emergencies (SAGE) used to advise the UK Government’s 
response 
UK Government | 20 March 2020 | News 
 https://www.gov.uk/government/news/coronavirus-covid-19-scientific-evidence-
supporting-the-uk-government-response 
 https://www.gov.uk/government/groups/scientific-advisory-group-for-emergencies-
sage-coronavirus-covid-19-response 
 
SARS-CoV-2 viral load in upper respiratory specimens of infected 
patients 
Zou et al. | NEJM | 19 March 2020 | Correspondence 
https://doi.org/10.1056/NEJMc2001737 
Viral load detected in the asymptomatic patient was similar to that in the symptomatic patients, 
suggesting the transmission potential of asymptomatic or minimally symptomatic patients. 
These findings concur with previous reports that transmission may occur early in the course 
of infection. Case detection and isolation may require strategies different from those required 
for the control of SARS-CoV where transmission occurred mainly after days of illness, was 
associated with modest viral loads in the respiratory tract early in the illness and will viral loads 
peaking approximately 10 days after symptom onset. 
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The coronavirus pandemic in five powerful charts 
Nature | 18 March 2020 | News 
https://www.nature.com/articles/d41586-020-00758-2 
This article publishes the coronavirus pandemic in five charts on (1) How is the coronavirus 
spreading around the world? (2) How does COVID-19 compare to other diseases? (3) How 
fast are researchers publishing new coronavirus research? (4) How have travel restrictions 
affect carbon emissions and air quality and (5) How does the current pandemic compare to 
the 2003 SARS outbreak? 
 
Impact of non-pharmaceutical interventions (NPIs) to reduce 
COVID-19 mortality and healthcare demand 
Ferguson et al. | Imperial College COVID-19 Response Team | 16 March 2020 | Report 
https://doi.org/10.25561/77482 
Results are reported of epidemiological modelling which has informed policymaking in the UK 
and other countries. Multiple interventions combined will be more effective than any one 
intervention. The effects of mitigation (slowing the epidemic spread) and suppression 
(reversing epidemic growth) strategies are discussed. Suppression will need to be maintained 
until a vaccine becomes available, given that it is predicted that transmission will quickly 
rebound if interventions are relaxed. Measures could be intermittent where reintroduction is 
guided by trends in disease surveillance.  
 
Publishers make coronavirus (COVID-19) content freely available 
and reusable 
Wellcome | 16 March 2020 | Press release 
https://wellcome.ac.uk/press-release/publishers-make-coronavirus-covid-19-content-freely-
available-and-reusable 
Following a request from science leaders to the publishing community, this press release lists 
more than 30 journals and publishers that have agreed to make all of their COVID-19 and 
coronavirus-related publications, and the data supporting them, accessible in PubMed Central 
(PMC) and reusable. This will accelerate global efforts to contain the SARS-CoV-2 virus, save 
lives and reduce societal disruption. 
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2. Tracking COVID-19 cases 
WHO COVID-19 daily situation reports 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports 
An interactive web-based dashboard to track COVID-19 in real time 
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd4029942
3467b48e9ecf6 
Africa Centres for Disease Control and Prevention (Africa CDC) 
http://www.africacdc.org/covid-19-and-resources 
Provides the latest situation updates for the African continent, information and guidance. 
COVID-19: PHE track coronavirus cases in the UK 
https://www.gov.uk/government/publications/covid-19-track-coronavirus-cases 
UK case tracing infographic 
https://www.arcgis.com/apps/opsdashboard/index.html#/f94c3c90da5b4e9f9a0b19484dd4b
b14 
South African Government COVID-19 
https://www.gov.za/Coronavirus 
3. Modelling and forecasting 
Preparing model for control measures against COVID-19 for wider use 
https://www.imperial.ac.uk/jameel-institute/ 
Imperial College London Jameel Institute for Disease and Emergency Analytics (J-IDEA) and 
MRC Centre for Global Infectious Disease Analysis are working with Microsoft and GitHub to 
prepare their code to model control measures against COVID-19, without extensive training. 
This will allow others to use without the multiple days training it would currently need. They 
are also helping to develop a web-based front end for public health policy makers worldwide 
to use the model in their planning. There is hope that v1 releases of both the source and front 
end in the next 7-10 days. Note that Neil Ferguson wrote the code (thousands of lines of 
undocumented C) 13+ years ago to model flu pandemics. 
Forecasting critical care bed requirements for COVID-19 patients in England 
Jombart et al. | Ongoing project work done within the Centre for Mathematical Modelling of 
Infectious Diseases at LSHTM | 22 March 2020 | Study yet to be peer reviewed 
https://cmmid.github.io/topics/covid19/current-patterns-transmission/ICU-projections.html 
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This ongoing modelling work forecasts that in all scenarios, despite substantial uncertainty, 
there will be a “marked” increase in need for beds in ICU/HDU, with average demand ranging 
from 1,931 (CI95%: 921 ; 4,361) to 4,364 (CI95%: 2,099 ; 9,568) critical care beds every day by 
the end of March 2020 (Table 1). This will challenge ICU/HDU capacity for COVID-19 in 
England (in January 2020: 4,123 critical beds for adults, 312 in paediatrics4) by the end of 
March, without even considering capacity requirements for other conditions, unless 
transmissibility is strongly reduced in the coming days.  
4. Online course 
COVID-19: Tackling the Novel Coronavirus 
LSHTM | FutureLearn course | Starts 23 March 2020 | 3 weeks | 4 hours weekly study | Free 
https://www.futurelearn.com/courses/covid19-novel-coronavirus 
A reminder that this course starts today. On this course you will learn what is known about the 
outbreak of COVID-19 (week 1); what the practical implications for responding to COVID-19 
are (week 2); and what we need to find out about COVID-19 (week 3). 
5. Resource Hubs 
Rapid guidelines and evidence reviews  
https://www.nice.org.uk/covid-19 
Note that NICE have waived their normal licensing requirement for international reuse or 
reproduction of their rapid guidelines and evidence reviews on COVID-19. The first 3 
guidelines cover care for people receiving critical care, kidney dialysis and systematic anticancer 
treatments. Rapid evidence reviews are currently being produced as to whether certain 
medicines may increase the severity or length of COVID-19 illness (i) ibuprofen and other non-
steroidal anti-inflammatory drugs used to reduce temperature and ease flu-like symptoms and 
(ii) angiotensin converting enzyme (ACE) inhibitors used to treat high blood pressure or heart 
failure. 
Imperial College London MRC Centre for Global Infectious Disease Analysis COVID-19 
reports 
https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-coronavirus/ 
Global research on COVID-19 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-
coronavirus-2019-ncovnovel-coronavirus-2019-ncov 
WHO R&D Blueprint 
https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/ 
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WHO: Coronavirus disease (COVID-19) outbreak resources 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019 
Latest information and advice from the UK Government 
https://www.gov.uk/guidance/coronavirus-covid-19-information-for-the-public 
CDC COVID-19 Resources 
https://www.cdc.gov/coronavirus/2019-ncov/index.html 
The Global Health Network Coronavirus outbreak knowledge hub 
https://coronavirus.tghn.org 
The Lancet COVID-19 Resource Centre 
https://www.thelancet.com/coronavirus 
Elsevier’s Novel Coronavirus Information Center 
https://www.elsevier.com/connect/coronavirus-information-center 
Cell Press Coronavirus Resource Hub 
https://www.cell.com/2019-nCOV 
Cochrane Special Collections - COVID-19: infection control and prevention measures 
https://www.cochranelibrary.com/collections/doi/SC000040/full 
The BMJ Coronavirus (covid-19): Latest news and resources 
https://www.bmj.com/coronavirus?int_source=wisepops&int_medium=wisepops&int_campai
gn=DAA_CoronaVirus_Jan24 
Johns Hopkins Coronavirus Resource Centre 
https://coronavirus.jhu.edu 
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